



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: James, Kenneth D., et al.

Group Art Unit: 1642

Serial Number: 10/723,933

Confirmation No.: 9468

Filed: November 26, 2003

For: NATRIURETIC COMPOUNDS, CONJUGATES, AND USES THEREOF

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.56 AND 37 C.F.R. § 1.97

It is respectfully requested that the document listed on the attached Form PTO/SB/08b be considered by the Patent and Trademark Office in the above-referenced application and made of record therein. A full text copy of the relevant document is enclosed. This information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last.

Respectfully submitted,

By:

William A. Barrett
Registration No. 42,296
Attorney for Applicant
Moore & Van Allen, PLLC
430 Davis Drive, Suite 500
Morrisville, NC 27560-6832
Phane: 010,286,8000

Phone: 919-286-8000 Facsimile: 919-286-8199

March 18, 2005

Date

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the US Postal Service as first class mail on March 18, 2005, in an envelope addressed to Commissioner of Patents, PO Box 1450, Alexandria, VA 22313-1450

Katrina Holland

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/F10				Complete if Known		
				Application Number	10/723,933	
THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	November 26, 2003	
				First Named Inventor	James, Kenneth D.	
				Art Unit	1642	
				Examiner Name		
(use as many sheets as necessary))			
Sheet	1	of	1	Attorney Docket Number	014811-205.108	

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article magazine, journal, serial, symposium, catalog, etc.), date, page(s), volucountry where published.	ume-issue num	ber(s), publisher, city and/or	T²		
	C1	MEHVAR, REZA; Modulation of the Pharmacokinetics and Pharma Glycol Conjugation; J. Pharm. Pharmacout Sci.; 3(1):125-136; 2000		of Proteins by Polyethylene			
				:			
Examiner			Date				
Signature			Considered				

Examiner	 Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.